Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Stock Picking for Charity - 2007 -- Ignore unavailable to you. Want to Upgrade?

To: Arthur Radley who wrote (26)	12/31/2006 7:14:32 PM
From: Arthur Radley	Read Replies (1) \| Respond to of 397

Rational for my picks: (ALZA).Wait to whether or not ALZA will be winning pick is short as they expect Phase IIB data in March, 2007. Migraine therapy is a huge market and ALZA delivery will be vast improvement over current intravenous method of delivery for the drug. About AZ-001 (Staccato prochlorperazine) AZ-001 combines Alexza's proprietary Staccato system with prochlorperazine, a drug belonging to the class of compounds known as phenothiazines. Prochlorperazine is currently approved in the United States for the treatment of several indications, including nausea and vomiting. In several published clinical studies, 10 mg of prochlorperazine administered intravenously demonstrated effective relief of migraine pain. The Company believes that AZ-001 could potentially result in a speed of therapeutic onset advantage over oral tablets, and a convenience and comfort advantage over injections. (CDTP)Strictly a long shot with grave concern about their cash position. But have to give these guys credit for getting national and international TV coverage for their three products. It is worth a visit to their website to view TV coverage for their cooling catheter and wound healing candidate. The Stanford law student that suffered the heart attack and was treated with the (CDTP) catheter product at Stanford Medical Center is amazing, when you consider he apparently suffered no brain function damage. (COLY) Is this going to be our Biotransplant stock for 2007, considering the number of those picking it for their portfolio? I hope that isn’t the case! (HNSN) I started a board here on SI that explains my thought on this one! Will be interesting race between IJ’s (STXS) pick and HNSN as to which company garners this market. (IDEV) With additional FDA approval for their first approved drug should speed their market penetration. Also, latest purchase is interesting venture into a new market. (MELA) Aging population and growing cases of melanoma and one would think that a better detection method than the human eye would be a given for dermatologist to add to their detection process. Strictly a long shot stock, but has performed well as of late. (MNTA) Showing up on most lists…..Biotransplant II or home run stock! Wait shouldn’t be long. (SNUS) Long wait and promises finally coming to an end! Could be another CTIC or a big winner! Jim McCamant has it for his stock of 2007, but then hasn’t he been wrong before? (VASC) Company is finally on the verge of becoming profitable. New products coming on board and if they get FDA approval for their thrombin production, will be major event of 2007.